Imfinzi Achieves European Milestone: First Immunotherapy to Improve Survival in Early Gastric Cancer

AstraZeneca has received European Commission approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy, a landmark achievement representing the first immunotherapy-based regimen to demonstrate survival benefits in early-stage gastric and…

Continue Reading Imfinzi Achieves European Milestone: First Immunotherapy to Improve Survival in Early Gastric Cancer

FASENRA Demonstrates Breakthrough Results in Rare Eosinophilic Disease: NATRON Trial Shows Promise for Hypereosinophilic Syndrome Patients

Hypereosinophilic syndrome (HES) patients may finally have a meaningful treatment option. According to an article published at BusinessWire.com, AstraZeneca's FASENRA (benralizumab) has shown statistically significant efficacy in delaying disease progression,…

Continue Reading FASENRA Demonstrates Breakthrough Results in Rare Eosinophilic Disease: NATRON Trial Shows Promise for Hypereosinophilic Syndrome Patients